Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
Delayed Quote. Delayed Nasdaq - 03/31 04:00:00 pm
202.73 USD   -2.76%
08:01pAMGEN : Establishes Wholly-Owned Affiliate In Japan
PR
07:46pAMGEN : 2019 Letter to Shareholders
PU
09:11aAMGEN : Update Regarding COVID-19 For Media
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Amgen: 1Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2019 | 04:12pm EDT

THOUSAND OAKS, Calif. (AP) _ Amgen Inc. (AMGN) on Tuesday reported first-quarter earnings of $1.99 billion.

On a per-share basis, the Thousand Oaks, California-based company said it had net income of $3.18. Earnings, adjusted for non-recurring costs, came to $3.56 per share.

The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $3.45 per share.

The world's largest biotech drugmaker posted revenue of $5.56 billion in the period, which matched Street forecasts.

Amgen expects full-year earnings in the range of $13.25 to $14.30 per share, with revenue in the range of $22 billion to $22.9 billion.

Amgen shares have declined 8% since the beginning of the year, while the Standard & Poor's 500 index has climbed 17%. In the final minutes of trading on Tuesday, shares hit $179.18, a rise of almost 3% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AMGN at https://www.zacks.com/ap/AMGN

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN INC.
08:01pAMGEN : Establishes Wholly-Owned Affiliate In Japan
PR
07:46pAMGEN : 2019 Letter to Shareholders
PU
09:11aAMGEN : Update Regarding COVID-19 For Media
PU
08:36aAMGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
03/23AMGEN : Update Regarding COVID-19 For Media
PU
03/23AMGEN : And The Amgen : Foundation Commit Up To $12.5 Million To Support COVID-1..
PR
03/20AMGEN : R&D Head Dr. David Reese Shares Perspective on COVID-19
PU
03/17AMGEN : Update Regarding COVID-19 For Media
PU
03/16Pharmaceutical Firms Curtailing In-Person Sales Calls to Doctors
DJ
03/16Pharmaceutical Firms Curtailing In-Person Sales Calls to Doctors
DJ
More news
Financials (USD)
Sales 2020 25 561 M
EBIT 2020 11 912 M
Net income 2020 7 123 M
Debt 2020 19 755 M
Yield 2020 3,13%
P/E ratio 2020 16,3x
P/E ratio 2021 14,2x
EV / Sales2020 5,45x
EV / Sales2021 5,16x
Capitalization 120 B
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 243,76  $
Last Close Price 202,73  $
Spread / Highest target 40,6%
Spread / Average Target 20,2%
Spread / Lowest Target -8,75%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-15.90%122 963
JOHNSON & JOHNSON-8.82%350 661
ROCHE HOLDING AG-5.53%273 496
MERCK & CO., INC-15.40%195 166
NOVARTIS-17.30%183 669
PFIZER, INC.-16.69%181 241